Abstract: The present disclosure provides crystalline forms of bictegravir, amorphous bictegravir sodium, amorphous solid dispersion of bictegravir sodium with pharmaceutically acceptable carrier and processes for the preparation thereof.

Abstract: Co-crystals of meloxicam co-formers can be prepared by co-crystallization from a polar solvent, such as aqueous dimethyl sulfoxide; or by slurry processes, such as with ethyl acetate. Such co-crystals have improved purities and are physically stable under storage for several months.

Abstract: The present disclosure provides crystalline forms of bictegravir, amorphous bictegravir sodium, amorphous solid dispersion of bictegravir sodium with pharmaceutically acceptable carrier and processes for the preparation thereof.

Abstract: The present invention provides a novel 1:1 co-crystal of (rac)-tramadol hydrobromide-celecoxib and processes for the preparation of the same by reacting (rac)-tramadol with hydrobromic acid and celecoxib. It also provides crystalline form of (rac)-tramadol hydrobromide.

Abstract: The present disclosure relates to crystalline forms of venetoclax and process for their preparation. The present disclosure also relates to process for preparation of amorphous venetoclax.

Abstract: An amorphous form of tenofovir alafenamide hemifumarate and process for the preparation of the same. A premix of amorphous tenofovir alafenamide hemifumarate with pharmaceutically acceptable excipients and process for the preparation of the same are also disclosed.

Abstract: The present disclosure provides novel crystalline sofosbuvir form-M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms.

Abstract: The amorphous form of trisodium sacubitril valsartan and methods for the preparation thereof are disclosed herein.

Abstract: The present disclosure provides solid forms of the hydrochloride salt of (5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide (Compound-A). In particular, an amorphous form, an ethyl acetate solvate form, a methyl n-butyl ketone solvate form, an anisole solvate form, an isobutyl acetate solvate form, a n-butyl acetate solvate form, a toluene solvate form, a 4-methyl-2-pentanol solvate form, a n-propyl acetate solvate form, a xylene solvate form, Form VIII and Form IX of the salt are disclosed. Processes for the preparation of each of the disclosed forms are also provided.

Abstract: The present disclosure provides amorphous lumacaftor, amorphous solid dispersions of lumacaftor, crystalline lumacaftor acetic acid solvate, crystalline lumacaftor ethyl acetate solvate, and processes for the preparation thereof. The lumacaftor forms disclosed herein may be useful for the preparation of oral dosage forms for treating cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases.

Abstract: The present disclosure relates to crystalline forms of venetoclax and process for their preparation. The present disclosure also relates to process for preparation of amorphous venetoclax.

Abstract: The present disclosure provides novel crystalline sofosbuvir form-M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms.

Abstract: The present disclosure provides amorphous lumacaftor, amorphous solid dispersions of lumacaftor, crystalline lumacaftor acetic acid solvate, crystalline lumacaftor ethyl acetate solvate, and processes for the preparation thereof. The lumacaftor forms disclosed herein may be useful for the preparation of oral dosage forms for treating cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases.

Abstract: The present disclosure provides amorphous ixazomib citrate and processes for the preparation thereof. Crystalline form M1, form M2, form M3, and form M4 of ixazomib citrate are also disclosed. The present disclosure also encompasses processes for the preparation of those crystalline forms.

Abstract: The present disclosure relates to novel crystalline dolutegravir sodium Form-M2, Form-M3, Form-M4 and process for the preparation thereof.

Abstract: The amorphous form of trisodium sacubitril valsartan and methods for the preparation thereof are disclosed herein.

Abstract: The present disclosure relates to amorphous and crystalline forms of 2-butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-,(2E)-, (2Z)-2-butenedioate (1:2) (afatinib dimaleate). The present disclosure also relates to process for the preparation of amorphous and crystalline forms of afatinib dimaleate. Further, the present disclosure relates to solid dispersion of amorphous afatinib dimaleate and the crystalline form of afatinib.

Abstract: The present disclosure provides novel crystalline forms of cabozantinib (S)-malate, designated as form-M1, M2, M3 and M4 and novel crystalline forms of cabozantinib free base, form-M1, M2 and M3 and methods of their production. The present disclosure also provides processes for the preparation of crystalline cabozantinib (S)-malate form N-1.

Abstract: The present disclosure relates to solid dispersion of amorphous empagliflozin and its process thereof.

Abstract: The present invention relates to novel and stable polymorphic forms of Perindopril (L)-Arginine designated as Form ? and amorphous form and processes for their preparation. The present invention also provides the novel polymorph Form ? with greater stability to heat and humidity and can be prepared on large scale by an efficient, economic and reproducible process.